Genome analyses and androgen quantification for an infant with 5α-reductase type 2 deficiency

J Pediatr Endocrinol Metab. 2021 Jun 24;34(9):1191-1195. doi: 10.1515/jpem-2020-0678. Print 2021 Sep 27.

Abstract

Objectives: 5α-reductase type 2 deficiency due to biallelic SRD5A2 variants is a common form of 46,XY disorders of sex development.

Case presentation: A Chinese neonate presented with ambiguous genitalia. He carried a homozygous likely_pathogenic SRD5A2 variant (c.650C>A, p.A217E). His apparently nonconsanguineous parents were heterozygotes for the variant. The variant has previously been identified in two Chinese patients. Our patient carried 14.2 Mb loss-of-heterogeneity regions distributed in the genome. The SRD5A2 variant in this family was invariably coupled with two polymorphisms in exon 1 and intron 1. In the patient, blood testosterone (T)/5α-dihydrotestosterone (5αDHT) ratios were elevated before and during mini puberty, and were higher when measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) than measured by conventional immune assays.

Conclusions: This study provides evidence for the founder effect of an SRD5A2 variant. Furthermore, our data indicate that there is a need to establish a new reference value for T/5αDHT ratios using LC-MS/MS.

Keywords: LC-MS/MS; T/5αDHT ratio; founder mutation.

Publication types

  • Case Reports

MeSH terms

  • 3-Oxo-5-alpha-Steroid 4-Dehydrogenase / deficiency
  • 3-Oxo-5-alpha-Steroid 4-Dehydrogenase / genetics*
  • Androgens / blood*
  • Disorder of Sex Development, 46,XY / blood
  • Disorder of Sex Development, 46,XY / genetics
  • Disorder of Sex Development, 46,XY / pathology*
  • Family
  • Humans
  • Infant
  • Male
  • Membrane Proteins / deficiency
  • Membrane Proteins / genetics*
  • Mutation*
  • Polymorphism, Single Nucleotide*
  • Prognosis

Substances

  • Androgens
  • Membrane Proteins
  • 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
  • SRD5A2 protein, human